In addition, HLA-DQA1/DQA2 were recently shown to be part of a predictive MHC class II signature for patient response, albeit in circulating T cells of ICI-treated patients with colorectal cancer (CRC) and patients with HNSCC.6 This evidence concerns the gene HLA-DQA1 and colorectal cancer.